Dr Vaishampayan on the Impact of TKI Combination Therapies in the Treatment of RCC
Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.
Stay updated with breaking news from Science Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.
Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.
Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.
Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.